RIBANNA 5th interim analysis: Matched-pair analysis of progression-free survival (PFS) across treatment cohorts and comparison of frontline ribociclib plus endocrine therapy PFS data from RIBANNA vs MONALEESA trials, in HR+, HER2-ABC

CANCER RESEARCH(2023)

引用 0|浏览9
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要